Prostate cancer management continues to rapidly evolve for men presenting with all stages of disease. In response to the pandemic of overdetection and overtreatment of indolent prostate cancer, active surveillance has become a standard management strategy for many men with low-risk cancers. Many challenges with clinical implementation of active surveillance persist, including optimal selection criteria, surveillance strategies, indicators of disease progression and when further treatment may be warranted.
